Full Fed. Circ. Told Teva Overreacting In Skinny Label IP Case
Teva's warning that a second split panel decision reviving GlaxoSmithKline's $235 million jury win over its heart failure drug Coreg will have a "seismic" impact on the drug industry is overblown,...To view the full article, register now.
Already a subscriber? Click here to view full article